PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas

Modern Pathology

Volumn 22, Issue 9, 2009, Pages 1243-1250

  Tung, Celestine S ^a   Mok, Samuel C ^a   Tsang, Yvonne T M ^a   Zu, Zhifei ^a   Song, Huijuan ^a   Liu, Jinsong ^a   Deavers, Michael T ^a   Malpica, Anais ^a   Wolf, Judith K ^a   Lu, Karen H ^a   Gershenson, David M ^a   Wong, Kwong Kwok ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarker; Borderline ovarian tumors; Gene expression; Low grade ovarian cancer; PAX2

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR PAX2;

ARTICLE; CANCER GRADING; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; PAX2 TRANSCRIPTION FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 69549127963     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.92     Document Type: Article

References (35)

1. American Cancer Society. Overview: Ovarian Cancer; How many women get ovarian cancer?. 2008 [cited 9-11-2008]; Available from:www.cancer.org.
2. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004;23:41-44. (Pubitemid 38018236)
3. Bertelsen K, Holund B, Andersen E. Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer. Int J Gynecol Cancer 1993;3:72-79. (Pubitemid 23209540)
4. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004;28:496-504. (Pubitemid 38436523)
5. Dehari R, Kurman RJ, Logani S, et al. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol 2007;31:1007-1012. (Pubitemid 47012296)
6. Gershenson DM, Sun CC, Lu KH, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 2006;108:361-368.
7. Auersperg N, Wong AS, Choi KC, et al. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-288. (Pubitemid 32458162)
8. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008;26:5284-5293.
9. Fathalla MF. Incessant ovulation - a factor in ovarian neoplasia? Lancet 1971;2:163.
10. Tong GX, Chiriboga L, Hamele-Bena D, et al. Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Mullerian system origin? Mod Pathol 2007;20:856-863.
11. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451-456.
12. Landen Jr CN, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008;26:995-1005.
13. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001;98:31-36. (Pubitemid 32095858)
14. Park DC, Yeo SG, Wilson MR, et al. Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Neoplasia 2008;10:964-972.
15. Silberstein GB, Dressler GR, Van Horn K. Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growth. Oncogene 2002;21:1009-1016. (Pubitemid 34174513)
16. Gnarra JR, Dressler GR. Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. Cancer Res 1995;55:4092-4098.
17. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005;29:218-224. (Pubitemid 40170640)
18. O'Neill CJ, Deavers MT, Malpica A, et al. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol 2005;29:1034-1041. (Pubitemid 41045547)
19. O'Neill CJ, McBride HA, Connolly LE, et al. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology 2007;50:773-779.
20. Bonome T, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005;65:10602-10612. (Pubitemid 41743756)
21. Wong KK, Lu KH, Malpica A, et al. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol 2007;26:404-409. (Pubitemid 47476325)
22. Longacre TA, McKenney JK, Tazelaar HD, et al. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol 2005;29:707-723.
23. Crispens MA, Bodurka D, Deavers M, et al. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 2002;99:3-10. (Pubitemid 34075460)
24. Silva EG, Gershenson DM, Malpica A, et al. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol 2006;30:1367-1371. (Pubitemid 44655469)
25. Chi N, Epstein JA. Getting your Pax straight: Pax proteins in development and disease. Trends Genet 2002;18:41-47. (Pubitemid 34031857)
26. Robson EJ, He SJ, Eccles MR. A PANorama of PAX genes in cancer and development. Nat Rev Cancer 2006;6:52-62.
27. Tong GX, Melamed J, Mansukhani M, et al. PAX2: a reliable marker for nephrogenic adenoma. Mod Pathol 2006;19:356-363. (Pubitemid 43276989)
28. Eccles MR, Schimmenti LA. Renal-coloboma syndrome: a multi-system developmental disorder caused by PAX2 mutations. Clin Genet 1999;56:1-9.
29. Khoubehi B, Kessling AM, Adshead JM, et al. Expression of the developmental and oncogenic PAX2 gene in human prostate cancer. J Urol 2001;165:2115-2120. (Pubitemid 32453564)
30. Dehbi M, Ghahremani M, Lechner M, et al. The paired-box transcription factor, PAX2, positively modulates expression of the Wilms' tumor suppressor gene (WT1). Oncogene 1996;13:447-453. (Pubitemid 26283840)
31. Buttiglieri S, Deregibus MC, Bravo S, et al. Role of Pax2 in apoptosis resistance and proinvasive phenotype of Kaposi's sarcoma cells. J Biol Chem 2004;279:4136-4143. (Pubitemid 38198998)
32. Torban E, Eccles MR, Favor J, et al. PAX2 suppresses apoptosis in renal collecting duct cells. Am J Pathol 2000;157:833-842. (Pubitemid 32109376)
33. Igarashi T, Ueda T, Suzuki H, et al. Aberrant expression of Pax-2 mRNA in renal cell carcinoma tissue and parenchyma of the affected kidney. Int J Urol 2001;8:60-64. (Pubitemid 32245344)
34. Muratovska A, Zhou C, He S, et al. Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 2003;22:7989-7997. (Pubitemid 37179944)
35. Hueber PA, Waters P, Clark P, et al. PAX2 inactivation enhances cisplatin-induced apoptosis in renal carcinoma cells. Kidney Int 2006;69:1139-1145.